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Aims High-mobility group box 1 (HMGB1) is a nuclear protein actively secreted by immune cells and passively released by
necrotic cells that initiates pro-inflammatory signalling through binding to the receptor for advance glycation end-pro-
ducts. HMGB1 has been established as a key inflammatory mediator during myocardial infarction, but the proximal
mechanisms responsible for myocardial HMGB1 expression and release in this setting remain unclear. Here, we
investigated the possible involvement of peroxynitrite, a potent cytotoxic oxidant formed during myocardial infarc-
tion, on these processes.
Methods
and results
The ability of peroxynitrite to induce necrosis and HMGB1 release in vitro was evaluated in H9c2 cardiomyoblasts and
in primary murine cardiac cells (myocytes and non-myocytes). In vivo, myocardial HMGB1 expression and nitrotyr-
osine content (a marker of peroxynitrite generation) were determined following myocardial ischaemia and reperfu-
sion in rats, whereas peroxynitrite formation was inhibited by two different peroxynitrite decomposition catalysts:
5,10,15,20-tetrakis(4-sulphonatophenyl) porphyrinato iron (III) (FeTPPS) or Mn(III)-tetrakis(4-benzoic acid) por-
phyrin chloride (MnTBAP). In all types of cells studied, peroxynitrite (100 mM) elicited significant necrosis, the
loss of intracellular HMGB1, and its passive release into the medium. In vivo, myocardial ischaemia–reperfusion
induced significant myocardial necrosis, cardiac nitrotyrosine formation, and marked overexpression of myocardial
HMGB1. FeTPPS reduced nitrotyrosine, decreased infarct size, and suppressed HMGB1 overexpression, an effect
that was similarly obtained with MnTBAP.
Conclusion These findings indicate that peroxynitrite represents a key mediator of HMGB1 overexpression and release by
cardiac cells and provide a novel mechanism linking myocardial oxidative/nitrosative stress with post-infarction myo-
cardial inflammation.
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1. Introduction
High-mobility group box 1 (HMGB1) is a nuclear protein implicated in
the binding of transcription factors to their cognate DNA sequences.
Furthermore, HMGB1 acts as a cytokine secreted by activated
immune cells and is also passively released by cells undergoing necro-
tic cell death, triggering inflammatory responses in neighbour cells
through its ability to bind the receptor for advanced glycation end-
product (RAGE) and to activate nuclear factor kappa B (NF-kB).1,2
A series of recent investigations indicated that HMGB1 is upregulated
and released by ischaemic tissues in vivo, including brain,3 liver,4 and
heart.5 With respect to the heart, elevated plasma levels of HMGB1
have been detected in patients after myocardial infarction and
appear correlated with adverse clinical outcomes.6 The emerging
* Corresponding author. Tel: +41 79 5564278, Fax: +41 21 3141384, Email: lucas.liaudet@chuv.ch
† The first two authors contributed equally to this work.
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2010. For permissions please email: journals.permissions@oup.com.
Cardiovascular Research (2011) 89, 586–594
doi:10.1093/cvr/cvq373
role of HMGB1 in the pathophysiology of myocardial infarction
remains controversial, with studies reporting detrimental
pro-inflammatory and cardiodepressive actions of HMGB1 in this
setting,5 and others indicating instead that HMGB1 may promote
the proliferation of cardiac stem cells, improve the healing process,
and reduce post-infarction myocardial dysfunction.6 –9
A major mechanism contributing to cell death during myocardial
ischaemia and reperfusion is the development of myocardial oxidative
stress and nitrosative stress, related to the formation of reactive
oxygen and reactive nitrogen species, most notably peroxynitrite,
formed from nitric oxide (NO) and superoxide (O2
2).10 Peroxynitrite
represents a key effector of cardiomyocyte cell death during myocar-
dial infarction via multiple mechanisms, including diffuse biomolecular
injury, DNA damage and secondary activation of poly(ADP-ribose)
polymerase, activation of metalloproteinases, and mitochondrial inhi-
bition as reviewed in Ferdinandy and Schulz11 and Pacher et al.12 The
toxicity of peroxynitrite towards cardiomyocytes suggests that it
might contribute to the release of HMGB1 during myocardial infarc-
tion. This would represent an important novel mechanism linking per-
oxynitrite not only with the acute myocardial damage triggered by
ischaemia and reperfusion, but also with the molecular signals
involved in the process of post-ischaemic inflammation, regeneration,
and healing. The present study was therefore designed to explore a
possible role of peroxynitrite in the process of HMGB1 release by
cardiac cells, using both in vitro and in vivo approaches. We found
that peroxynitrite induces the release of significant amounts of
HMGB1 by cardiac cells in vitro (myocytes and non-myocytes) and
also represents a key regulator of HMGB1 expression in the infarcted
myocardium. These data identify a previously unrecognized role of
peroxynitrite in the complex pathophysiology of myocardial ischae-
mia–reperfusion injury.
2. Methods
All the animal experiments were approved by the State Government
Veterinary Office (Lausanne, Switzerland) and were performed according
to the University of Lausanne Medical School institutional guidelines. The
investigation conforms with the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH Publication
No. 85-23, revised 1996).
2.1 Cell culture conditions and stimulation
H9c2 cells, a clonal line derived from rat heart,13,14 were grown (5% CO2,
378C) in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco BRL, Invi-
trogen, Basel, Switzerland) supplemented with 10% foetal bovine serum
(FBS), 100 U/mL penicillin, and 0.1 mg/mL streptomycin. H9c2 cells
retain several morphological and metabolic characteristics of embryonic
cardiocytes and are recognized as a well-suited model to study cardio-
myocyte biology.15 However, given the inherent limitations of cell lines,
we performed most in vitro experiments in primary murine cardiac cells.
Neonatal C57BL/6 mice (Charles River Laboratories) were used as a
source of ventricular cardiomyocytes and mesenchymal non-myocyte
cells (NMCs), according to previously published procedures.16 Briefly,
ventricles were separated from the atria, minced, and digested in buffer
containing 0.45 mg/mL collagenase (Worthington Biochemical Corpor-
ation, Lakewood, NJ, USA) and 1 mg/mL pancreatin (Invitrogen Life
Technologies, Basel, Switzerland). Cardiomyocytes and NMCs were sep-
arated by two steps of differential plating at 45 min each. Adherent cells,
reflecting the NMC fraction, were expanded in culture in a 3:1 mixture of
DMEM and Medium 199 (Invitrogen Life Technologies, Basel, Switzerland)
supplemented with 10% horse serum (Serotech Ltd, Oxford, UK), 5% FBS
(Serotech Ltd), 100 U/mL penicillin G, and 100 g/mL streptomycin. Cardi-
omyocytes were plated on gelatinized plates in the same medium, allowed
to adhere overnight, and then maintained in serum-free medium with
antibiotics.
Peroxynitrite (Calbiochem, Calbiochemi, Merck Chemicals, Darmstadt,
Germany) was synthesized from isoamyl nitrite and hydrogen peroxide
followed by removal of hydrogen peroxide over a manganese dioxide
column, as described,17 and was stored in 0.4 M NaOH at 2808C.
Prior to experimentation, the concentration of peroxynitrite was deter-
mined from its absorption at 302 nm (extinction coefficient of 1670/M/
cm). Stimulations were performed in phosphate-buffered saline (PBS) to
avoid reactions of peroxynitrite with media constituents.13,18 Peroxyni-
trite was delivered as a single bolus at a 1:100 dilution, at a final concen-
tration of 100 mM. This concentration was used on the basis of pilot
experiments, showing that it was sufficient to induce significant cell necro-
sis. This concentration has physiological relevance, since it has been esti-
mated that rates of peroxynitrite production up to 50–100 mM/min could
be reached in specific compartments in vivo.19 It is also worth mentioning
that the actual effective concentration of peroxynitrite experienced by
cells should be expressed as a concentration × time product.20 There-
fore, sustained production of low micromolar concentrations of peroxy-
nitrite would produce effects comparable to a single bolus addition of
higher concentrations of peroxynitrite, as performed in the current
study. After 40 min of stimulation, the cells were replaced in the culture
medium and were then examined after 1–4 h.
2.2 Cytotoxicity assays and evaluation of
necrosis and apoptosis
The release of lactate deshydrogenase (LDH) in the culture medium was
determined as an indicator of cell necrosis,21 using a commercially avail-
able kit (Roche Molecular Biochemicals, Basel, Switzerland), as per man-
ufacturer’s protocol. The release of troponin I by cardiac myocytes was
further used as an indicator of necrosis, using the ACCESSw 2 cardiac tro-
ponin I immunoassay system from Beckman Coulter (Brea, CA, USA). In a
subset of experiments, necrosis was also measured in H9c2 cells by the
propidium iodide (PI) staining method. At the end of stimulation, cells
were stained with 1 mg/mL PI (Molecular Probes, Eugene, OR, USA) for
30 min and washed twice with PBS+2% FBS, and necrosis was then ana-
lysed by a FacsCalibur flow cytometer (Beckton–Dickinson, San Jose, CA,
USA), as described previously.22
The influence of peroxynitrite on the development of apoptosis was
also evaluated in a subset of cardiac cells (non-myocytes). At the end of
stimulation, cells were washed (PBS+2% FBS), and incubated with PI
and Annexin V conjugated to the fluorochrome CyTM5 (Pharmingen,
Allschwil, Switzerland) for 15 min, and then fluorescence activated cell
sorting (FACS) sorted. Living, apoptotic, and necrotic cells were then
used to evaluate the intracellular expression of HMGB1 by western blot-
ting, as exposed below.
Contrast-phase microscopic evaluation was performed for the mor-
phological assessment of cytotoxicity.
2.3 Immunoblot detection of HMGB1, RAGE,
and TLR4
Cells were scraped in lysis buffer (Tris–HCl 10 mM, NP40 0.5%, NaCl
0.15 M, Na3VO4 1 mM, NaF 10 mM, phenylmethanesulfonylfluoride
(PMSF) 1 mM, EDTA 1 mM, aprotinin 10 mg/mL, leupeptin 10 mg/mL,
and pepstatin 1 mg/mL). Proteins (20 mg) were separated by sodium
dodecyl sulphate–polyacrylamide gel electrophoresis, transferred to
nitrocellulose membrane, and blocked for 1 h at room temperature
with 5% non-fat dry milk in Tris-buffered saline containing 0.1%
Tween-20. The membrane was then incubated overnight at 48C with
primary antibodies raised against HMGB1 (Assay Designs, Ann Arbor,
MI, USA), RAGE (ABCAM, Cambridge, MA, USA), or toll-like receptor
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4 (TLR4) (a kind gift from Dr Thierry Roger, Service of Infectious Dis-
eases, Lausanne University Hospital, Switzerland), followed by incubation
for 1 h with a 1:5000 dilution of horseradish peroxidase-conjugated sec-
ondary antibody (Bio-Rad, Hercules, CA, USA).
2.4 HMGB1 assay in cell medium
After stimulation, the cell medium was aspirated, cleared by centrifu-
gation, and assayed for the release of HMGB1 using a commercially avail-
able ELISA (Shino-Test Corporation, Tokyo), according to the instructions
provided by the manufacturer.
2.5 RNA isolation and reverse transcriptase–
polymerase chain reaction
RNA isolation and reverse transcription were performed as described,13
using the following primer pairs: RAGE (sense, 5′-GAAGGCTCTGTGG
GTGAGTC-3′; antisense, 5′-ATTCAGCTCTGCACGTTCCT-3′) and
TLR4 (sense, 5′-CAGCAAAGTCCCTGATGACA-3′; anti-sense, 5′-AGA
GGTGGTGTAAGCCATGC-3′).
2.6 Myocardial ischaemia–reperfusion in rats
Adult male Wistar rats (300–350 g) were anaesthetized with intraperito-
neal thiopentone sodium (60 mg kg21), tracheostomized, and mechani-
cally ventilated (Harvard Model 683 rodent respirator, Holliston, MA,
USA). Core temperature was maintained at 378C. Following a left thora-
cotomy, the left anterior descending coronary artery was ligated by an
intramural 5.0 silk suture and a snare occluder. After 45 min of ischaemia,
reperfusion was allowed for 1, 2, or 6 h by removing the coronary occlu-
der. Rats were treated 10 min before reperfusion with 10 mg/kg
5,10,15,20-tetrakis(4-sulhonatophenyl) porphyrinato iron (III) chloride
(FeTPPS), a metalloporphyrin peroxynitrite decomposition catalyst,23,24
or isotonic saline (0.5 mL), given intravenously. A group of sham rats
not exposed to myocardial ischaemia–reperfusion was used for control
purpose. At the end of the reperfusion period, hearts were removed
for the determination of myocardial infarct size (2 h reperfusion) and
for the evaluation of the expression levels of HMGB1 and nitrotyrosine
(1 h reperfusion) within the cardiac tissue (discussed subsequently). In
addition, cardiac HMGB1 expression was also determined (after 2 h
reperfusion) in cardiac samples from a previous experimental study,14 in
which rats exposed to the same protocol of myocardial ischaemia–
Figure 1 Peroxynitrite induces necrosis of H9c2 cardiomyoblasts and the passive release of HMGB1. H9c2 cells were exposed to 100–250 mM
peroxynitrite for 40 min and then replaced in the culture medium for a total of 4 h. Cell necrosis was evaluated by propidium iodide staining and FACS
analysis (A) and by the release of LDH (B). The release of HMGB1 into the cell medium was determined by enzyme-linked immunosorbent assay (C).
The cellular content of HMGB1 was determined by western blotting (D). Tubulin is shown as a loading control. Morphological evaluation of cells was
performed by a phase-contrast microscope 2 and 4 h after peroxynitrite (100 mM) treatment (E). Cont: control, unstimulated cells. Graphs show
means+ SEM of at least three independent observations. *P, 0.05, t-test.
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reperfusion were treated with Mn(III)-tetrakis(4-benzoic acid) porphyrin
chloride (MnTBAP), a stable and cell-permeable superoxide dismutase
mimetic and peroxynitrite decomposition catalyst (1 mg/kg intraperitone-
ally 20 min before and 30 and 60 min after reperfusion).
2.6.1 Determination of myocardial infarct size
Area at risk (AAR) and infarct size were determined using the triphenyl-
tetrazolium chloride-Evans Blue technique, as described.14 The AAR and
the infarcted area were expressed as percentage values according to con-
ventional methods (AAR/left ventricle and infarcted area/AAR).
2.6.2 Protein extraction and immunoblot detection of
HMGB1 and nitrotyrosine
Heart tissue was homogenized (50 mg/mL) in lysis buffer (Tris–HCl
10 mM, NP40 0.5%, NaCl 0.15 M, Na3VO4 1 mM, NaF 10 mM, PMSF
1 mM, EDTA 1 mM, aprotinin 10 mg/mL, leupeptin 10 mg/mL, and
pepstatin 1 mg/mL). Western immunoblotting (30 mg myocardial proteins)
was performed as described earlier, using anti-HMGB1 (Assay Designs)
or mouse monoclonal anti-nitrotyrosine (Cayman Chemical, Ann Arbor,
MI, USA) primary antibodies. Densitometric analysis of enhanced chemilu-
minescence autoradiographs was performed using a Personal Densitometer
and TotalLab Software.
2.7 Presentation of data and statistical analysis
All graphs present data as means+ SE. When only two conditions were
compared, analysis was performed by Student’s t-test. In experiments with
more than two conditions, statistical analysis was performed using analysis
of variance (ANOVA), followed by Tukey’s adjustments when appropri-
ate. Statistical significance was ascribed to P, 0.05.
3. Results
3.1 Peroxynitrite provokes necrosis of
cardiac cells and their passive release of
HMGB1 in vitro
H9c2 cardiomyoblasts exposed to 100–250 mM peroxynitrite dis-
closed significant PI staining as shown by the FACS analysis, with
the proportion of necrotic cells reaching 48 and 65%, respectively
(Figure 1A). In contrast, cells treated with NaOH (PN vehicle) did
not show any significant increase in PI staining when compared with
untreated control cells. The concentration of 100 mM peroxynitrite
was then used for all other in vitro experiments. As shown in
Figure 1B, such concentrations induced significant release of LDH
Figure 2 Necrosis and passive release of HMGB1 are induced by peroxynitrite in primary murine cardiomyocytes and non-myocyte cells. Neonatal
murine cardiomyocytes (left panel) and non-myocyte cells (middle panel) exposed to 100 mM peroxynitrite for 40 min and then replaced in the
culture medium for a total of 4 h disclosed significant necrosis, as shown by LDH release (A), as well as by passive release of HMGB1, as shown
by the liberation of HMGB1within the cell medium [(B) ELISA] and the disappearance of intracellular HMGB1 [(C), western immunoblotting].
Tubulin is shown as a loading control. Morphological evaluation of cells was performed by a phase-contrast microscope 2 and 4 h after peroxynitrite
(D). The kinetics of HMGB1 (E) and troponin I (F) release by cardiomyocytes was evaluated from 1 to 4 h after peroxynitrite stimulation. Cont:
control, unstimulated cells. Graphs show means+ SEM of at least three independent observations. *P, 0.05, t-test.
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within the cell medium, and this was associated with a marked
increase in HMGB1 in the cell medium (Figure 1C), occurring in paral-
lel to a profound reduction in the cellular expression of HMGB1
(Figure 1D). Thus, the enhanced HMGB1 signal in the cell medium
was due to passive release, but not to increased HMGB1 expression.
The expression of a-tubulin, used as a loading control (Figure 1D),
did not change between untreated and peroxynitrite-treated cells,
implying that a-tubulin remained confined within the cellular
protein pool and that the release of HMGB1 was not a general
process affecting all cellular proteins. Morphological evaluation of
H9c2 cells treated with peroxynitrite is shown in Figure 1E. Obvious
signs of cytotoxicity were detected after 2 h and further increased
after 4 h.
We then evaluated the effects of peroxynitrite on primary cardiac
cells obtained from neonatal mice, which contain both a myocyte and
a non-myocyte fraction. Both types of cells disclosed significant
necrosis upon peroxynitrite treatment (LDH release, Figure 2A),
accompanied by the passive release of HMGB1 within the cell
medium (HMGB1 in medium, Figure 2B; HMGB1 cellular expression,
Figure 2C). Of note, cardiac myocytes appeared more sensitive to the
toxic effects of peroxynitrite, as shown by a much greater increase in
LDH in the medium. Morphological evaluation showed marked signs
of cytotoxicity of peroxynitrite, both after 2 and 4 h, as illustrated in
Figure 2D. Finally, the kinetics of HMGB1 release by cardiac myocytes
was compared with that of troponin I. As shown in Figure 2E and F,
both HMGB1 and troponin I disclosed a progressive and comparable
increase in the cell medium after peroxynitrite stimulation, further
demonstrating the link between necrosis and the release of HMGB1.
3.2 Cardiac cells express the HMGB1
receptors: RAGE and TLR4
As indicated in Figure 3A (reverse transcriptase–polymerase chain
reaction) and B (western immunoblotting), cardiomyocytes and
NMCs express RAGE and TLR4, both at the mRNA and protein
level, implying that these cells might have the ability to be targeted
by HMGB1.
3.3 Peroxynitrite-induced apoptosis does
not trigger the release of HMGB1 by
cardiac cells in vitro
NMCs treated with peroxynitrite were stained with PI and CyTM5
Annexin V and were then FACS sorted as indicated in Figure 4A.
Viable cells were both Annexin V- and PI-negative, apoptotic cells
were Annexin V-positive and PI-negative, whereas necrotic cells
were PI-positive. The expression level of HMGB1 was then deter-
mined by western immunoblotting in each cell subpopulation. As
shown in Figure 4B, HMGB1 expression could not be detected in
necrotic cells, indicative of its passive release. In contrast, HMGB1
expression was still observed in apoptotic cells similar to viable
cells, implying that cells dying by apoptosis retained HMGB1
intracellularly.
3.4 Myocardial necrosis triggered by
ischaemia–reperfusion is associated with an
increased expression of HMGB1 within the
myocardium
Figure 5A illustrates the large area of myocardial necrosis (whitish zone
within the left ventricular free wall) induced by 45 min ischaemia,
followed by 2 h reperfusion in the rat. The expression of HMGB1 is
shown in Figure 5B. In sham rats not exposed to ischaemia, HMGB1
was detected at a low level, but this level increased significantly
after 1 h reperfusion, further increased after 2 h reperfusion, and
then persisted at an elevated level after 6 h, with no further increase
in comparison to 2 h. Compared with baseline conditions, the
expression levels of HMGB1 increased by 2.6+0.4-, 6.9+1.7-, and
4.1+0.5-fold after 1, 2, and 6 h reperfusion, respectively.
3.5 Peroxynitrite decomposition catalysts
reduce infarct size, decrease cardiac
nitrotyrosine accumulation, and suppress
HMGB1 upregulation in the reperfused
myocardium
There was no difference in the ischaemic area (AAR) between control
animals and animals treated with FeTPPS (Figure 6A). In contrast,
FeTPPS provided significant protection against myocardial injury, as
shown by a reduction in infarct size (in per cent of the AAR) from
46+ 1 to 25+6% (P, 0.05, Figure 6A), which compares well with
the protective effect of MnTBAP (13+4%) reported in our previous
works.14 Myocardial ischaemia–reperfusion also resulted in a signifi-
cant increase in the myocardial nitrotyrosine content (used as a
marker for the generation of peroxynitrite), which was significantly
reduced with FeTPPS (Figure 6B), to an extent similar to that
reported earlier with MnTBAP.14 In addition, the increased expression
of HMGB1 triggered by 1 and 2 h reperfusion could be markedly
Figure 3 Cardiac cells express the HMGB1 receptors: RAGE and
TLR4 receptor-4. These expressions were evaluated at the mRNA
level [reverse transcriptase–polymerase chain reaction (A)] and at
the protein level [western immunoblotting (B)] in cardiomyocytes
(cardios) and non-myocytes (non-myocyte cells). The expression
levels of ribosomal S18 mRNA and tubulin protein are shown as
loading controls.
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suppressed by FeTPPS (1 h reperfusion, Figure 6B) and MnTBAP (2 h
reperfusion, Figure 6C). The myocardial expression of Akt (Figure 6B)
and tubulin (Figure 6C), used as internal controls, did not show any
variations in the different conditions studied.
4. Discussion
The major novel finding of this study is that peroxynitrite promotes
significant release of HMGB1 by cardiac cells in vitro and also rep-
resents a key effector of increased HMGB1 expression in the myocar-
dium exposed to ischemia–reperfusion.
Emerging evidence indicates that molecules released by damaged
tissues act as internal danger signals, triggering innate immune
defence mechanisms comparable to those triggered by external
signals released by invading pathogens.25 HMGB1, a ubiquitous
nuclear protein promoting transcriptional activation, represents a
major member of such ‘danger-associated molecular patterns’,
which is passively released by cells undergoing necrotic (but not apop-
totic) cell death.2 HMGB1 exerts its pro-inflammatory activity by
binding to the RAGE, as well as to TLR4.26,27
Recent observations support an important role of HMGB1, RAGE,
and TLR4 in promoting innate immune defence mechanisms and
inflammatory responses in the heart exposed to ischaemia–reperfusion
(reviewed in Volz et al.28). Indeed, HMGB1 is released by hypoxic car-
diomyocytes in vitro5 and is upregulated in the infarcted myocardium in
vivo,5,6 and strategies neutralizing HMGB1 or its receptors attenuate
myocardial inflammation after myocardial infarction.5,29,30 Importantly,
HMGB1 may not only foster detrimental pro-inflammatory effects in
the myocardium, but might also be important for the successful adap-
tation of the heart to injury, as supported by studies reporting ben-
eficial actions of HMGB1 on the process of adverse cardiac
remodelling.6,7 Besides HMGB1, it is also worth noting that additional
candidate molecules might be able to trigger TLR (or RAGE)-
dependent innate immune response after myocardial infarction,
including S100 proteins,31 the heat shock protein (HSP) 70,32 as
well as the extracellular matrix protein fibronectin EDA.33
One of the earliest pathophysiological mechanisms of myocardial
reperfusion injury is the generation of significant amounts of
oxygen- and nitrogen-centred free radicals and oxidants, triggered
by the re-oxygenation of the previously anoxic myocardium.34
Accumulating evidence indicates that peroxynitrite, formed from
Figure 4 Necrotic cells, but not apoptotic, released HMGB1 upon
peroxynitrite stimulation. Cardiac non-myocyte cells treated with
100 mM peroxynitrite for 40 min followed by 4 h in the culture
medium were stained with propidium iodide and CyTM5 Annexin
V and were analysed by FACS. (A) Viable cells (P1) are Annexin V-
and propidium iodide-negative; apoptotic cells (P2) are Annexin
V-positive and propidium iodide-negative; and necrotic cells (P3)
are propidium iodide-positive. (B) Expression of HMGB1 in viable,
necrotic, and apoptotic cells. Necrotic cells, but not apoptotic,
released HMGB1 (loss of intracellular HMGB1 signal). Tubulin is
shown as loading control. Blots are representative of three indepen-
dent experiments.
Figure 5 High-mobility group box 1 expression is upregulated in
the myocardium exposed to ischaemia–reperfusion. Rats were
exposed to 45 min myocardial ischaemia followed by 1, 2, or 6 h
reperfusion. A group of rats not exposed to ischaemia were used
for control purposes. (A) Myocardial slices stained with Evan’s Blue
and triphenyl-tetrazolium chloride show significant necrosis after
2 h reperfusion (blue, perfused area; red, living tissue within the
ischaemic area; white, necrotic tissue within the ischaemic area).
(B) Myocardial expression of HMGB1, evaluated by western
immunoblotting. A significant increase in HMGB1expression was
noted after 1–6 h reperfusion. Graphs show means+ SEM of
n ¼ 3–5 rats/group. *P, 0.05, analysis of variance followed by
Tukey’s test.
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the diffusion-controlled reaction between NO and the superoxide
radical O2,
210,35 represents a major oxidant and nitrating species trig-
gering significant myocardial damage in this setting.11,12 Accordingly,
therapeutic strategies reducing peroxynitrite have been associated
with significant cardioprotection during myocardial ischaemia and
reperfusion.14,36,37
In the present study, we report a previously unrecognized link
between peroxynitrite and HMGB1, which may be important to
understand the connections between oxidative/nitrosative stress
and inflammation in the reperfused myocardium. In vitro, peroxynitrite
induced significant necrosis of H9c2 cells, which then released large
amounts of HMGB1, as indicated by the reduction in cellular
HMGB1 levels concomitant to a large increase in extracellular
HMGB1. More importantly, primary mouse cardiomyocytes, as well
as the non-myocyte fraction of cardiac cells (which includes fibro-
blasts, endothelial and smooth muscle vascular cells, as well as
cardiac progenitor cells) exhibited a response similar to peroxynitrite,
that is, cell necrosis and the complete release of HMGB1 in the extra-
cellular milieu. Interestingly, the release of HMGB1 and LDH by
cardiomyocytes was approximately twice higher than that of non-
myocytes, suggesting that cardiac myocytes may be more sensitive
to the cytotoxic actions of peroxynitrite. This may be consistent
with the reported higher sensitivity of cardiomyocytes to anoxo/
ischaemic injury in comparison to the much greater resistance of non-
myocytes, especially fibroblasts.38
Peroxynitrite also induced apoptotic cell death, as evaluated in the
non-myocyte fraction, in agreement with our previous report on
peroxynitrite-induced cytotoxicity in cardiac cells.14 However, at
variance with necrotic cells, apoptotic cells retained HMGB1 intra-
cellularly, implying that the passive release of HMGB1 was restricted
to cells dying by necrosis, but not by apoptosis, which perfectly
concurs with previous findings obtained in unrelated types of cells
(reviewed in Raucci et al.39). These findings clearly indicate that an
important consequence of peroxynitrite exposure in all subtypes of
cardiac cells is the massive liberation of HMGB1, in line with the
concept of passive HMGB1 release by cells dying by necrosis.2,4,5
Finally, we also found that both cardiac myocytes and non-myocytes
express RAGE and TLR4, the two major cell surface receptors inter-
acting with extracellular HMGB1.26,27 This supports the contention
that HMGB1 released by necrotic cardiac cells might induce
HMGB1-dependent signalling in neighbour viable cells, a hypothesis
that should be investigated in future studies.
We then determined whether peroxynitrite might also influence
HMGB1 in vivo, using a rat model of myocardial ischaemia–
Figure 6 Peroxynitrite decomposition catalysts reduce myocardial necrosis and suppress myocardial HMGB1 overexpression induced by ischae-
mia–reperfusion. Rats challenged with 45 min myocardial ischaemia followed by reperfusion (1–2 h) were left untreated or were treated with
FeTPPS (10 mg/kg i.v.), given 10 min before reperfusion, or with MnTBAP (1 mg/kg i.p. 20 min before and 30 and 60 min after reperfusion). Sham
rats not exposed to ischaemia–reperfusion were used for control purposes. (A) Reduction of infarct size by FeTPPS (2 h reperfusion). Infarct size
is expressed in per cent of the area at risk. Means+ SEM of n ¼ 4 rats/group. *P, 0.05, t-test. (B) Reduction of myocardial nitrotyrosine and
HMGB1 expression by FeTPPS (1 h reperfusion). Means+ SEM of n ¼ 3–4 rats/group. *P, 0.05, analysis of variance followed by Tukey’s test.
(C) Suppression of myocardial overexpression of HMGB1 by MnTBAP (2 h reperfusion). Means+ SEM of n ¼ 3–5 rats/group. *P, 0.05, analysis
of variance followed by Tukey’s test.
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reperfusion injury. In such conditions, we first noticed that the
expression level of HMGB1 within the myocardium was significantly
increased after reperfusion. HMGB1 expression increased already
after 1 h, was maximal after 2 h reperfusion, and then persisted at
comparable levels after prolonged reperfusion (6 h). These findings
are in line with a previous observation in mice, showing that both
HMGB1 mRNA and protein levels were upregulated as early as
30 min after myocardial reperfusion.5 Also, it is worth mentioning
that such an increased expression of HMGB1 has been reported in
the liver in a murine model of hepatic ischaemia/reperfusion.4 These
data suggest that both passive release and upregulated expression
of HMGB1 concur to promote post-ischaemic inflammation in reper-
fused organs. Since we did not determine which cell population con-
tributed to the increased HMGB1 level in the heart, we cannot rule
out that overexpression of HMGB1 was due, at least in part, to inflam-
matory cells. Indeed, in rats exposed to permanent coronary occlu-
sion, HMGB1 expression was enhanced not only in cardiomyocytes
but also in infiltrating inflammatory cells.6 However, cardiac myocytes
might represent a major source of HMGB1, as suggested by a recent
study in mice showing marked overexpression of HMGB1 in these
cells upon treatment with endotoxin, implying that cardiomyocytes
can be converted to an immune/inflammatory phenotype under
stressful conditions in vivo.40
Our second key observation in vivo was that FeTPPS suppressed
myocardial upregulation of HMGB1 observed after 1 h reperfusion,
an effect correlated with the reduced accumulation of nitrotyrosine,
a marker of nitrative stress, and more specifically peroxynitrite gener-
ation,10,41 and a similar reduction of HMGB1 expression was obtained
with MnTBAP after 2 h reperfusion. In addition, FeTPPS significantly
reduced myocardial infarct size to an extent comparable to our pre-
vious findings with MnTBAP14 and to those of other investigators
using two unrelated peroxynitrite decomposition catalysts, FP1542
and INO4885.37 Coupled to our in vitro findings, these data imply a
causative role of peroxynitrite not only as an effector of myocardial
cell death, but also as a proximal mediator triggering cardiac
HMGB1 expression and release during myocardial infarction.
Although the pharmacological reduction of peroxynitrite has been
associated with reduced inflammation in reperfused organs,14,43,44 the
mechanisms underlying such link between peroxynitrite and post-
ischaemic inflammation remain incompletely understood. It has
been proposed that peroxynitrite (and, more generally, reactive
oxygen and nitrogen species) might directly activate the
pro-inflammatory transcription NF-kB,45,46 but this issue remains
highly controversial.47,48 Indeed, recent findings have indicated that,
under some conditions, oxidants (including peroxynitrite) do not acti-
vate, but instead inhibit NF-kB.18,49 On the basis of our current
results, we may therefore propose an alternative mechanism connect-
ing peroxynitrite and myocardial inflammation, based on HMGB1
release and upregulation during myocardial reperfusion.
In conclusion, this study provides the first experimental demon-
stration implicating peroxynitrite as a key mediator of HMGB1
release by cardiac cells (myocytic and non-myocytic) in vitro and of
myocardial HMGB1 upregulation in ischaemia/reperfusion. In view
of the emerging pro-inflammatory role of HMGB1 in such conditions,
our findings provide a novel insight into the mechanisms linking oxi-
dative/nitrosative stress and post-ischaemic inflammation in the
myocardium.
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